Your browser doesn't support javascript.
A distinct innate immune signature marks progression from mild to severe COVID-19.
Chevrier, Stéphane; Zurbuchen, Yves; Cervia, Carlo; Adamo, Sarah; Raeber, Miro E; de Souza, Natalie; Sivapatham, Sujana; Jacobs, Andrea; Bachli, Esther; Rudiger, Alain; Stüssi-Helbling, Melina; Huber, Lars C; Schaer, Dominik J; Nilsson, Jakob; Boyman, Onur; Bodenmiller, Bernd.
  • Chevrier S; Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
  • Zurbuchen Y; Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.
  • Cervia C; Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.
  • Adamo S; Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.
  • Raeber ME; Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.
  • de Souza N; Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.
  • Sivapatham S; Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
  • Jacobs A; Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.
  • Bachli E; Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland.
  • Rudiger A; Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
  • Stüssi-Helbling M; Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.
  • Huber LC; Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
  • Schaer DJ; Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.
  • Nilsson J; Clinic for Internal Medicine, Uster Hospital, Uster, Switzerland.
  • Boyman O; Department of Medicine, Limmattal Hospital, Schlieren, Switzerland.
  • Bodenmiller B; Clinic for Internal Medicine, City Hospital Triemli Zurich, Zurich, Switzerland.
Cell Rep Med ; 2(1): 100166, 2021 01 19.
Article in English | MEDLINE | ID: covidwho-989408
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Coronavirus disease 2019 (COVID-19) manifests with a range of severities, but immune signatures of mild and severe disease are still not fully understood. Here, we use mass cytometry and targeted proteomics to profile the innate immune response of patients with mild or severe COVID-19 and of healthy individuals. Sampling at different stages allows us to reconstruct a pseudo-temporal trajectory of the innate response. A surge of CD169+ monocytes associated with an IFN-γ+MCP-2+ signature rapidly follows symptom onset. At later stages, we observe a persistent inflammatory phenotype in patients with severe disease, dominated by high CCL3 and CCL4 abundance correlating with the re-appearance of CD16+ monocytes, whereas the response of mild COVID-19 patients normalizes. Our data provide insights into the dynamic nature of inflammatory responses in COVID-19 patients and identify sustained innate immune responses as a likely mechanism in severe patients, thus supporting the investigation of targeted interventions in severe COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Immunity, Innate Type of study: Prognostic study Topics: Long Covid Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: Cell Rep Med Year: 2021 Document Type: Article Affiliation country: J.xcrm.2020.100166

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Immunity, Innate Type of study: Prognostic study Topics: Long Covid Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: Cell Rep Med Year: 2021 Document Type: Article Affiliation country: J.xcrm.2020.100166